Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...

Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, said: “This groundbreaking decision to fund the UK’s first ever Crispr-based therapy for patients with sickle cell disorder ...

A student from Oxfordshire is going to be one of the first to receive a cutting-edge treatment for sickle cell disease ... licensed using gene-editing tool Crispr, which earned its inventors ...

In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was ...

Treatment for sickle cell disease, the most common inherited blood disorder in Kenya, has been approved for use in England for older children and adults with a severe form of the disease.The treatment ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.